NMS 293
Alternative Names: NMS-03305293; NMS-293; NMS-P293Latest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Astrocytoma; Glioblastoma
- Phase I Solid tumours
- No development reported Breast cancer
Most Recent Events
- 13 Jan 2025 US FDA approves regulatory application for NMS 293 in Small cell lung cancer and Ovarian cancer
- 13 Jan 2025 Nerviano Medical Sciences plans a phase I trial for Ovarian cancer (Combination therapy) (PO)
- 13 Jan 2025 Nerviano Medical Sciences plans a phase I trial for Small cell lung cancer (Combination therapy) (PO)